Additional Chalcogen Attached Directly Or Indirectly To The Diazine Ring By Nonionic Bonding Patents (Class 544/318)
-
Patent number: 10844283Abstract: A polymerizable liquid crystal compound represented by formula (1). In formula (1), A1 is 1,4-phenylene, 1,4-cyclohexylene, 1,4-cyclohexenylene, pyridine-2,5-diyl, 1,3-dioxane-2,5-diyl or naphthalene-2,6-diyl, Z1 is a connecting group, m and n are independently an integer from 0 to 5, in which an expression: 1?m+n?8 holds, X1 is alkylene having 1 to 5 carbons, in which an atom thereof may be replaced by a hetero atom, and at least one of R1 is a polymerizable functional group.Type: GrantFiled: February 13, 2018Date of Patent: November 24, 2020Assignees: JNC CORPORATION, JNC PETROCHEMICAL CORPORATIONInventor: Daisuke Ootsuki
-
Patent number: 10166530Abstract: Disclosed is a method for reducing organic compounds using catalysts containing nickel (0) from metal hyperaccumulator plants. The method can be implemented in a green manner and is advantageous compared to methods using the known catalysts.Type: GrantFiled: July 15, 2015Date of Patent: January 1, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE MONTPELLIERInventors: Claude Grison, Vincent Escande
-
Patent number: 9834518Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: wherein the variables are as defined herein.Type: GrantFiled: May 4, 2012Date of Patent: December 5, 2017Assignee: ARIAD Pharmaceuticals, Inc.Inventors: David C. Dalgarno, Wei-Sheng Huang, William C. Shakespeare, Yihan Wang, Xiaotian Zhu
-
Patent number: 9174944Abstract: This invention relates to novel crystalline lopinavir/surfactant adducts, methods for their preparation, therapeutic uses of those crystalline lopinavir/surfactant adducts, and pharmaceutical compositions containing them or made from them.Type: GrantFiled: December 16, 2011Date of Patent: November 3, 2015Assignee: ABBVIE INC.Inventors: Yuchuan Gong, Geoff G. Zhang, Matthias Degenhardt, Markus Maegerlein
-
Patent number: 9040698Abstract: Disclosed is a method for preparing optically pure (+)-ambrisentan and (+)-darusentan, comprising: firstly catalyzing the asymmetric epoxidation of a ?-unsaturated alkene using a chiral ketone derived from fructose or a hydrate thereof as a catalyst, and then subjecting the product to an epoxy compound ring-opening reaction and substitution reaction successively to obtain optically pure (+)-ambrisentan and (+)-darusentan.Type: GrantFiled: July 1, 2011Date of Patent: May 26, 2015Assignee: Institute of Chemistry Chinese Academy of SciencesInventors: Yian Shi, Xianyou Peng, Peijun Li
-
Patent number: 9034888Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R7, R6, R7, R8, R9, A, X and Y as defined herein are provided as useful for the treatment of cancer or for the manufacture of anti-cancer agents.Type: GrantFiled: February 16, 2011Date of Patent: May 19, 2015Assignee: Universite LavalInventors: René C. Gaudreault, Sébastien Fortin
-
Patent number: 8987250Abstract: Compounds disclosed herein including compounds of formula I?: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.Type: GrantFiled: April 19, 2013Date of Patent: March 24, 2015Assignee: Gilead Sciences, Inc.Inventors: Kerim Babaoglu, Gediminas Brizgys, Jake Cha, Xiaowu Chen, Hongyan Guo, Randall L. Halcomb, Xiaochun Han, Richard Huang, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Yingmei Qi, Paul A. Roethle, Lianhong Xu, Hong Yang
-
Patent number: 8962832Abstract: The invention relates to improved processes for the preparation of ambrisentan. The invention also relates to a novel intermediate useful in the preparation of ambrisentan and a process for the preparation of the intermediate. The invention also relates to new polymorphic form of ambrisentan. In particular, it relates to a polymorphic form, designated as Form I of ambrisentan and a process for the preparation of the Form I.Type: GrantFiled: July 12, 2010Date of Patent: February 24, 2015Assignee: Cadila Healthcare LimitedInventors: Kaushik Babubhai Sata, Bipin Pandey
-
Publication number: 20150031709Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: ApplicationFiled: February 8, 2013Publication date: January 29, 2015Applicant: SUNOVION PHARMACEUTICALS, INC.Inventors: John Emmerson Campbell, Una Campbell, Taleen G. Hanania, Liming Shao
-
Patent number: 8933090Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.Type: GrantFiled: October 19, 2010Date of Patent: January 13, 2015Assignee: Novartis AGInventors: Dominik Feuerbach, Werner Müller, Bernard Lucien Roy, Thomas J. Troxler, Konstanze Hurth, Mathias Frederiksen
-
Publication number: 20150005295Abstract: Inhibitors of HBV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1-R5, B and Z have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.Type: ApplicationFiled: January 4, 2013Publication date: January 1, 2015Inventors: Koen Vandyck, Geerwin Yvonne Paul Haché, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Raboisson
-
Patent number: 8901314Abstract: The present invention relates to compounds of Formula (I), wherein X1, X2, X3, X4, R1, R2, R3, and Q are as defined herein, useful as N-type calcium channel blockers.Type: GrantFiled: August 16, 2013Date of Patent: December 2, 2014Assignee: Janssen Pharmaceutica NVInventors: Mark Wall, Nalin Subasinghe, Zhihua Sui, Christopher Flores
-
Publication number: 20140350015Abstract: The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and/or prevention of cancer.Type: ApplicationFiled: June 12, 2014Publication date: November 27, 2014Inventors: Edward McDonald, Julian Blagg, Mark Pichowicz, Simon Ross Crumpler
-
Patent number: 8865623Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.Type: GrantFiled: January 6, 2010Date of Patent: October 21, 2014Assignee: Syngenta LimitedInventors: Christopher John Mathews, John Finney, James Nicholas Scutt, Louisa Robinson, John Stephen Delaney
-
Publication number: 20140309237Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: June 26, 2014Publication date: October 16, 2014Inventors: Jeffrey P. WHITTEN, Jonathan GREY, Jianguo CAO, Zhijun WANG, Evan ROGERS
-
Publication number: 20140296232Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:Type: ApplicationFiled: March 27, 2014Publication date: October 2, 2014Applicants: Massachusetts General Hospital, The Broad Institute, Inc.Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
-
Publication number: 20140256004Abstract: The present invention relates to a novel process for the preparation of a compound of formula (I) wherein R is a methyl or methoxy group; to certain novel intermediates prepared in such a process and their use.Type: ApplicationFiled: October 19, 2012Publication date: September 11, 2014Applicant: CIPLA LIMITEDInventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Sanjay Naik, Maruti Ghagare, Sandip Vasant Chikhalikar
-
Publication number: 20140249309Abstract: Disclosed is a method for preparing optically pure (+)-ambrisentan and (+)-darusentan, comprising: firstly catalyzing the asymmetric epoxidation of a ?-unsaturated alkene using a chiral ketone derived from fructose or a hydrate thereof as a catalyst, and then subjecting the product to an epoxy compound ring-opening reaction and substitution reaction successively to obtain optically pure (+)-ambrisentan and (+)-darusentan.Type: ApplicationFiled: July 1, 2011Publication date: September 4, 2014Applicant: INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCESInventors: Yian Shi, Xianyou Peng, Peijun Li
-
Publication number: 20140235660Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.Type: ApplicationFiled: February 12, 2014Publication date: August 21, 2014Applicant: NOVARTIS AGInventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
-
Patent number: 8809357Abstract: The present invention relates to compounds of formula (I), a derivative, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer; methods of preparation of the same; and methods of counducting drug discovery and research by applying the same in an investigation.Type: GrantFiled: May 20, 2010Date of Patent: August 19, 2014Inventor: Zhen Huang
-
Publication number: 20140228219Abstract: The present invention provides a compound having an excellent efficacy for controlling weeds. A cyclohexanone compound of the formula (I): wherein m is an integer of 1, 2 or 3; n is an integer of any one of 1 to 5; X represents CH2, O, S, S(O) or S(O)2; R1 represents a hydrogen atom or a methyl group; R2 and R3 represents a hydrogen atom, a C1-6 alkyl group and the like; R4 represents a C6-10 aryl group or a five- to six-membered heteroaryl group; G represents a hydrogen atom and the like; Z represents a halogen atom, a cyano group, a nitro group, a phenyl group, a C1-6 alkyl group and the like; is useful as an active ingredient for herbicides.Type: ApplicationFiled: May 29, 2012Publication date: August 14, 2014Inventors: Yosuke Nakashima, Yoshinobu Jin, Masato Konobe
-
Publication number: 20140227302Abstract: Disclosed herein are compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.Type: ApplicationFiled: September 4, 2012Publication date: August 14, 2014Inventors: Wen-Lian Wu, Duane A. Burnett
-
Patent number: 8779127Abstract: The present invention provides a facile process for the preparation of tri- and tetra—substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora—mediated diseases or conditions.Type: GrantFiled: August 15, 2012Date of Patent: July 15, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, Francesca Mazzei, David Kay, Andrew Miller
-
Publication number: 20140171639Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicant: AMGEN INC.Inventors: Kaustav Biswas, James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Vu Van Ma, Holger Monenschein, Thomas T. Nguyen, David J. St. Jean, JR., Chester Chenguang Yuan, Wenge Zhong
-
Patent number: 8748444Abstract: Disclosed are compounds represented by Formula (I): or pharmaceutically acceptable salts, enantiomers or diastereomers thereof. Also disclosed are pharmaceutical compositions comprising the compounds of Formula (I) or pharmaceutically acceptable salts, enantiomers or diastereomers thereof and methods of inhibiting 11 ?-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (I) or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Values for the variables of Formula (I) are defined herein.Type: GrantFiled: April 30, 2013Date of Patent: June 10, 2014Assignee: Vitae Pharmaceuticals, Inc.Inventors: Salvacion Cacatian, David A. Claremon, Wei He, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Wei Zhao, Linghang Zhuang
-
Publication number: 20140155594Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.Type: ApplicationFiled: April 24, 2013Publication date: June 5, 2014Applicant: Cancer Research Technology LimitedInventors: Grégoire Alexandre Pavé, James Donald Firth, Lorna Stewart, Laurent Jean Martin Rigoreau, Emma Louise Stanway
-
Patent number: 8729092Abstract: The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including AIDS, cancer, and Alzheimer's Disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3R,5R), (3S,5R), or (3S,5S) configurations, or pharmaceutically acceptable salts thereof. Biologically-active rosuvastatin enantiomer compounds with (3R,5R), (3S,5R), and (3S,5S) stereochemistry are also disclosed.Type: GrantFiled: September 24, 2012Date of Patent: May 20, 2014Inventor: Terence J. Scallen
-
Patent number: 8703938Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with the compounds.Type: GrantFiled: September 10, 2010Date of Patent: April 22, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Ce Wang, Lu Ying, Xiaowen Peng, Yao-Ling Qiu
-
Patent number: 8686007Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 12, 2012Date of Patent: April 1, 2014Assignee: Cytokinetics, Inc.Inventors: Luke W. Ashcraft, Gustave Bergnes, Chihyuan Chuang, Scott Collibee, Pu-Ping Lu, Bradley Morgan, Alex Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang
-
Publication number: 20140031376Abstract: The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Shigeyuki ITOH, Atsushi IWATA
-
Publication number: 20140005181Abstract: The present disclosure relates to compounds and methods for treating a disease mediated by apelin.Type: ApplicationFiled: June 20, 2013Publication date: January 2, 2014Applicant: Sanford-Burnham Medical Research InstituteInventors: Layton Smith, Anthony B. Pinkerton
-
Publication number: 20130345219Abstract: The present invention relates to compounds according to formulae (IA) to (ID) and compositions that inhibit the activity of Hsp90. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: Synta Pharmaceuticals Corp.Inventors: Chi-Wan Lee, Teresa Prezewloka, Weiwen Ying, Minghu Song, Zhenjian Du, Kevin Foley, Dan Zhou, Shuzhen Qin
-
Publication number: 20130324409Abstract: The present invention provides methods of regulating plant stress tolerance.Type: ApplicationFiled: March 14, 2013Publication date: December 5, 2013Inventors: SEAN R. CUTLER, ANDREW DEFRIES
-
Patent number: 8598365Abstract: Bicyclic dione compounds, and derivatives thereof, which are suitable for use as herbicides.Type: GrantFiled: July 30, 2008Date of Patent: December 3, 2013Assignee: Syngenta LimitedInventors: Stephane André Marie Jeanmart, Christopher John Mathews, John Benjamin Taylor, Steve Smith
-
Publication number: 20130310347Abstract: High throughput methods for identifying novel inhibitors of Hsp90 chaperone protein folding are disclosed. The inhibitors so identified disrupt the binding of p23 to either Hsp90? or Hsp90? and have selective activity against the proliferation of cancer cells. In particular are provided embodiments of therapeutic compositions that comprise at least one inhibitor of an Hsp90 chaperone activity, the inhibitor being any of the compounds designated as CP1-CP19 as shown in FIGS. 1A-1D or a 2-(trifluoromethyl)pyrimidin-2-yl)thio)acetamide derivatives.Type: ApplicationFiled: May 21, 2013Publication date: November 21, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Carmel Chan, Sanjiv S. Gambhir, David E. Solow-Cordero, Aileen Hoehne, Ramasamy Paulmurugan
-
Patent number: 8575342Abstract: Compounds of formula (I), N-oxides, pharmaceutical acceptable salts, quaternary amines or stereoisomeric forms thereof, and their use as HIV replication inhibitors, In the formula, -a1=a2-a3=a4- and -b1=b2-b3=b4- may be —C?C—C?C—; X1 may be O, NR1, etc.; R1, R2, R2a, R3, R4 and R5 are assorted substituents as defined in the specification.Type: GrantFiled: September 29, 2005Date of Patent: November 5, 2013Assignee: Tibotech Pharmaceuticals Ltd.Inventors: Jerôme Emile Georges Guillemont, Jan Heeres, Paulus Joannes Lewi
-
Publication number: 20130281433Abstract: Compounds disclosed herein including compounds of formula I?: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.Type: ApplicationFiled: April 19, 2013Publication date: October 24, 2013Inventors: Kerim Babaoglu, Gediminas Brizgys, Jake Cha, Xiaowu Chen, Hongyan Guo, Randall L. Halcomb, Xiaochun Han, Richard Huang, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Yingmei Qi, Paul A. Roethle, Lianhong Xu, Hong Yang
-
Publication number: 20130267546Abstract: The present disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof: compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation.Type: ApplicationFiled: April 2, 2013Publication date: October 10, 2013Applicant: Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of AriInventors: Sidney HECHT, Omar KHDOUR, Jun LU, Pablo ARCE
-
Publication number: 20130267564Abstract: A benzyloxypyrimidine derivative represented by the formula (I) wherein R1 is an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a haloalkenyl group, a haloalkynyl group, an alkoxyalkyl group and the like; R2 and R3 are each a hydrogen atom, an alkyl group and the like; X is an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a haloalkenyl group, a haloalkynyl group, a trialkylsilyl group and the like; A is a oxygen atom and the like, and m is an integer of 0-5, or a salt thereof, and an agrohorticultural insecticide containing the compound as an active ingredient and a method of use thereof.Type: ApplicationFiled: December 22, 2011Publication date: October 10, 2013Applicant: NIHON NOHYAKU CO., LTD.Inventors: Ryota Kasahara, Hiroto Harayama, Eikou Satoh, Motofumi Nakano, Kosuke Fukatsu, Kayo Inukai
-
Publication number: 20130252937Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.Type: ApplicationFiled: March 14, 2013Publication date: September 26, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Matthias ECKHARDT, Sara FRATTINI, Dieter HAMPRECHT, Frank HIMMELSBACH, Elke LANGKOPF, Iain LINGARD, Stefan PETERS, Holger WAGNER
-
Patent number: 8541594Abstract: Bicyclic dione compounds, and derivatives thereof, which are suitable for use as herbicides.Type: GrantFiled: July 30, 2008Date of Patent: September 24, 2013Assignee: Syngenta LimitedInventors: Stephane André Marie Jeanmart, Christopher John Mathews, John Benjamin Taylor, Steve Smith
-
Publication number: 20130245063Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: April 26, 2013Publication date: September 19, 2013Applicant: CalciMedica, Inc.Inventors: Jeffrey P. Whitten, Jonathan Grey, Jianguo Cao, Zhijun Wang, Evan Rogers
-
Publication number: 20130245051Abstract: This invention relates to novel compounds of the Formula (I), (Ia) and (Ib), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, j which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 ?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell Or the inhibition of the conversion of cortisone to Cortisol in a cell.Type: ApplicationFiled: April 30, 2013Publication date: September 19, 2013Applicant: VITAE PHARMACEUTICALS, INC.Inventors: David A. Claremon, Linghang Zhuang, Colin M. Tice, Yuanjie Ye, Wei He, Suresh B. Singh, Zhenrong Xu, Salvacion Cacatian, Wei Zhao
-
Patent number: 8530667Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, are suitable for use as herbicides.Type: GrantFiled: September 1, 2008Date of Patent: September 10, 2013Assignee: Syngenta LimitedInventors: Stephane André Marie Jeanmart, John Benjamin Taylor, Melloney Tyte, Christopher John Mathews, Stephen Christopher Smith
-
Patent number: 8530461Abstract: Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.Type: GrantFiled: December 14, 2012Date of Patent: September 10, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Bernd Nosse, Martin Fleck, Niklas Heine, Gerald Juergen Roth
-
Patent number: 8512820Abstract: Ionic mesogenic compounds of formula (I) can be used to form liquid crystal displays, such as ferroelectric liquid crystal displays, having enhanced anti-image sticking properties. The mesogenic compounds may contain a cationic group such as an ammonium or phosphonium group bonded to an alkyl chain that is terminally bonded to a para-substituted pyrimidyl benzene moiety. The counterion can be an organic or inorganic anion. The compounds can be used either as dopants in art ferroelectric liquid crystal compositions to reduce image sticking, or can be used as the primary or predominant component of a liquid crystal display system. Additional compounds, devices, and methods are disclosed.Type: GrantFiled: June 14, 2011Date of Patent: August 20, 2013Assignee: Citizen Finetech Miyota Co., Ltd.Inventors: Yongqiang Zhang, Su Yang
-
Patent number: 8513244Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R4, and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: May 18, 2012Date of Patent: August 20, 2013Assignee: Theravance, Inc.Inventors: Roland Gendron, Adam D. Hughes
-
Patent number: 8507485Abstract: A method of treating a disease associated with angiogenesis by administering a therapeutically effective amount of a compound represented by the formula (1) or a salt thereof wherein the ring X represents R1 and R2 independently represent a hydrogen atom, an alkyl, an aryl or an aromatic heterocyclic; R3 represents a hydrogen atom, a halogen atom, a hydroxy, an alkoxy, an aryloxy, an alkyl, an aryl, an amino, an alkylamino, a cycloalkylamino, an arylamino, an alkylcarbonylamino, an arylcarbonylamino, a mercapto, an alkylthio, an arylthio, an alkylsulfinyl or a nonaromatic heterocyclic; A1 represents a sulfur atom, a sulfinyl or a sulfonyl; and A2 represents an alkylene.Type: GrantFiled: January 24, 2011Date of Patent: August 13, 2013Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hisashi Tajima, Takahiro Honda, Kenji Kawashima, Kazuyoshi Okamoto, Minoru Yamamoto
-
Publication number: 20130203727Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).Type: ApplicationFiled: July 1, 2011Publication date: August 8, 2013Applicant: GILEAD SCIENCES, INC.Inventors: Kerim Babaoglu, Elizabeth Bacon, Kyla Bjornson, Hongyan Guo, Randall L. Halcomb, Paul Hrvatin, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Paul Roethle, James Taylor, James D. Trenkle, Randall W. Vivian, Lianhong Xu
-
Publication number: 20130203790Abstract: Novel sulphur-containing compounds and pharmaceutically acceptable salts thereof are disclosed, which have utility as anti-proliferative agents against mammalian cells. The invention provides a method for synthesizing the sulphur-containing compounds.Type: ApplicationFiled: July 9, 2012Publication date: August 8, 2013Applicant: 221076 ONTARIO INC.Inventors: Dheeraj RAJAN, Mark Otto BAERLOCHER